Skip to content

Efficacy and Safety of Anrikefon Injection for Postoperative Analgesia in Adults Undergoing Cholecystectomy: A Prospective, Randomized, Controlled, Non-inferiority Trial

Efficacy and Safety of Anrikefon Injection for Postoperative Analgesia in Adults Undergoing Cholecystectomy: A Prospective, Randomized, Controlled, Non-inferiority Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117757
Enrollment
Unknown
Registered
2026-01-28
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Experimental Group:Thirty minutes before the start of surgery, a loading dose of Anrikefon at 1.0 µg/kg, diluted in 10 mL of 0.9% normal saline, will be administered intravenously over more than 2 min
Control group:30 minutes before surgery, butorphanol 6.0 µg/kg was administered intravenously as a loading dose (based on the equivalent dose conversion of remifentanil and morphine). After surgery, t

Sponsors

The Second Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years, no gender restriction; 2. Patients scheduled for elective laparoscopic cholecystectomy; 3. ASA score I–III; 4. Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Expected hospital stay <48 hours; 2. Patients expected to enter the ICU postoperatively; 3. Patients expected to require mechanical ventilation support postoperatively; 4. Known allergy to the active ingredient or excipients of Enricfen injection; 5. Patients with severe consciousness disorders or mental illnesses (schizophrenia, mania, bipolar disorder, psychosis, etc.) and cognitive impairment; 6. History of serious cardiovascular disease (such as congestive heart failure, severe angina attacks, or unstable angina or myocardial infarction within the past 6 months); 7. Pregnant or breastfeeding patients; 8. Patients with an MMSE score <18; 9. Patients with poorly controlled or untreated hypertension (arterial hypertension with resting systolic blood pressure over 180 mmHg or resting diastolic blood pressure over 100 mmHg); 10. Untreated or inadequately treated hyperthyroidism; 11. Recent opioid abuse history (e.g., within the past 3 months).

Design outcomes

Primary

MeasureTime frame
Numeric Rating Scale (NRS) pain scores within 48 hours postoperatively;

Secondary

MeasureTime frame
Total opioid consumption within 48 hours postoperatively (converted to morphine-equivalent dose);; Time to first rescue analgesic administration and its incidence after surgery;Time to emergence from anesthesia;Incidence of intraoperative adverse events;

Countries

China

Contacts

Public ContactMuhuo Ji

The Second Affiliated Hospital of Nanjing Medical University

jimuhuo2009@sina.com+86 159 9623 5006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026